Ipamorelin: inspect the offer

A rather good molecule. A much larger claim.

The word “buy” rushes toward a decision. I prefer the moment before it, with the object turned over and the flattering description put beside its actual record. Ipamorelin rewards that closer inspection: the chemistry is interesting, while the reputation asks rather more of it.

In the founding animal experiments, this synthetic peptide released growth hormone without the ACTH and cortisol rise seen with older growth-hormone-releasing peptides. “Selective” was earned there, in rat pituitary cells, rats and pigs. It describes a hormone response under those test conditions.

The next leap is the troublesome one. Community accounts describe better sleep, recovery and a leaner appearance; those are anecdotal accounts, not clinical evidence. The published trial in bowel-surgery patients did not meet its primary endpoint. I grant the molecule its narrow achievement. I don’t grant it the rest on credit.

Bowel-resection results in adults

A drug that appears in discussions of body composition went into a human trial about eating after bowel surgery. That is a revealing mismatch between its public reputation and its clinical record.

In the trial reported in 2014, 114 adults received Ipamorelin or placebo. Median time to the first tolerated meal was 25.3 h with Ipamorelin and 32.6 h with placebo, with p=0.15. The study missed its primary endpoint. The lower number looks attractive in isolation; the trial did not establish the benefit it set out to test.

That result deserves its own room. The clinical record follows the experiment through its outcome, rather than borrowing its participants to support a claim about sleep or fat.

Animal weight findings

The weight papers are particularly awkward for an easy fat-loss story. Ipamorelin increased adiposity in mice, including GH-deficient mice. In ferrets receiving cisplatin, it inhibited body-weight loss by approximately 24% in the reported delayed phase, without preventing vomiting. These were animal experiments, and keeping weight on sick ferrets is a different objective from taking fat off people.

I value an awkward weight result that spoils a tidy sales pitch. They make the molecule more interesting and the pitch less convincing. Effects and risks gives these results space beside the personal reports.

Choose the thing to inspect

The identity page starts with a synthetic chain shortened from an older peptide. The mechanism page follows the hormone pulse and the places where “GH-selective” gets stretched too far. Study amounts retain the subjects and routes alongside the numbers. The research has validated no home regimen.

Ipamorelin has never been approved as a medicine. Its research record is worth examining without turning that interest into an assurance about treatment.